

#AAD2019

Highlights **AEDV**

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

Scientific Initiative of:



Sponsored by:



#AAD2019

Highlights **AEDV**

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

Psoriasis Dr. Manel Velasco

Scientific Initiative of:



Sponsored by:



S036:PSORIASIS. LEBWOHL

Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

DRUG	PsA	OBESITY	CARDIAC	CA	+ANA	LUPUS	MS	CROHN UC	HEPATITIS C Ab +	HBsAg+	Anti-HBc+
ETANERCEPT	+	+	+	-	+	+/-	X	+	+	-	+/-*
ADALIMUMAB	+	+	+	-	+	+/-	X	+	+	-	+/-*
INFLIXIMAB	+	+	+	-	+	+/-	X	+	+	-	+/-*
CERTOLIZUMAB	+	+	+	-	+	+	X	+	+	-	+/-*
USTEKINUMAB	+	+	+	-	+	+	+	+	-	?+/-*	?/+*
SECUKINUMAB	+	+	?	+/-	+	+	+	X	?/+*	?+*	?/+*
IXEKIZUMAB	+	+	?	+/-	+	+	+	X	?/+*	?+*	?/+*
BRODALUMAB	+	+	?	+/-	+	+	+	X	?/+*	?+*	?/+*
GUSELKUMAB	+	+	?	+/-	+	+	+	+	?	?	?
TILDRAKIZUMAB	?+	+	?	+/-	+	+	+	+	?	?	?
RISANKIZUMAB	?+	+	?	+/-	+	+	+	+	?	?	?
MIRIKIZUMAB	?+	+	?	+/-	+	+	+	+	?	?	?
APREMILAST	+	+	?	+/-	+	+	+	+	?/+*	?	?
METHOTREXATE	+	X	+	-	+	+	+	+	X	X	X
CYCLOSPORINE	+/-	+	?/-	X	+	+/-	+	+	+/-*	X	X
ACITRETIN	+/-	+	?/-	+	+	+	+	? X	+	+	+

S036:PSORIASIS. LEBWOHL

Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

DRUG	CHF	Latent TB	Pregnancy	Pediatric	Speed	Palm/Sole	Pustular	Erythrodermic
ETANERCEPT	-/+	+						
ADALIMUMAB	-/+	+						
INFLIXIMAB	-/+	+						
CERTOLIZUMAB	-/+	+						
USTEKINUMAB	+	+						
SECUKINUMAB	+	+						
IXEKIZUMAB	+	+						
BRODALUMAB	+	+						
GUSELKUMAB	+	+						
TILDRAKIZUMAB	+	+						
RISANKIZUMAB	+	+						
MIRIKIZUMAB	+	+						
APREMILAST	+	+						
METHOTREXATE	+	+						
CYCLOSPORINE	+	+						
ACITREFTIN	+	+						

S036: PSORIASIS. BLAUVET

Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

FUTURE BIOLOGIC AND ORAL DRUG CHOICES FOR MODERATE-TO-SEVERE PSORIASIS

- Etanercept (Enbrel®)
- Infliximab (Remicade®)
- Adalimumab (Humira®)
- Ustekinumab (Stelara®)
- Secukinumab (Cosentyx®)
- Ixekizumab (Taltz®)
- Brodalumab (Siliq®)
- Guselkumab (Tremfya®)
- Tildrakizumab (Ilumya®)
- Certolizumab (Cimzia®)
- **Risankizumab**
- **Bimekizumab**
- **Mirikizumab**
- Methotrexate
- Cyclosporine
- Acitretin
- Apremilast (Otezla®)
- **BMS-986165**



S036: PSORIASIS. BLAUVET. SKYRILZI


Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

GUSELKUMAB, TILDRAKIZUMAB, RISANKIZUMAB, AND MIRIKIZUMAB SELECTIVELY BLOCK IL-23



S036: PSORIASIS. BLAUVET. SKYRILZI


Highlights
AEDV

IN 77th AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

RISANKIZUMAB, AN IL-23 BLOCKER, IMPROVES PSORIASIS BETTER THAN USTEKINUMAB (PASI 90, week 52, phase 3)



REF: Gordon, ..., Blauvelt et al, *Lancet*, 2018



S036: PSORIASIS. BLAUVET



Highlights
AEDV

IN 77th AAD CONGRESS


1-5 MARCH 2019

★ WASHINGTON ★

MIRIKIZUMAB, AN IL-23 BLOCKER, IMPROVES PSORIASIS (PASI 90/sPGA 0/1, week 16, phase 2)



REF: Reich et al, *Br J Dermatol*, 2019



S036: PSORIASIS. BLAUVET

Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

RISANKIZUMAB SUMMARY

- **Efficacy**: excellent, higher than other IL-23 blockers on market
- **Durability**: excellent, maintained over 1 year
- **Other relevant diseases**: effective for **PsA** and **Crohn's disease**, but not ankylosing spondylitis
- **Safety**: excellent, no concerns thus far
- **Convenience**: very convenient (**every 3 months**)
- **Cost/accessibility**: ? (FDA approval likely in **spring 2019**)



S036: PSORIASIS. BLAUVET

Highlights
AEDV

IN 77TH AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

MIRIKIZUMAB SUMMARY

- **Efficacy**: excellent, initially less high than other IL-23 blockers on market (phase 2), however, phase 3 dosing increased
- **Durability**: excellent, maintained over 1 year
- **Other relevant diseases**: effective for **ulcerative colitis**
- **Safety**: excellent, no concerns thus far
- **Convenience**: very convenient (**every 2-3 months**)
- **Cost/accessibility**: ? (FDA approval in **2021?**)



Brodalumab in the treatment of moderate-to-severe psoriasis in patients who have previously failed treatment with anti-interleukin-17A therapies.

*Grace Kimmel MD, Margot Chima MD, Hee Jin Kim MD, Christopher Yao MPH, Giselle Singer BS, and Mark Lebwohl MD.
Icahn School of Medicine at Mount Sinai*


- 39 p
- Failed to ixekizumab or secukinumab
- Brodalumab 16 w
- PASI 75: 76%
- PASI 90: 50%
- PASI 100: 32%

Efficacy of Switching to Risankizumab Compared With Continued Adalimumab Treatment in Patients With Moderate-to-Severe Plaque Psoriasis

8110

Caitriona Ryan, MD¹; Jeffrey Crowley, MD²; Wendell C Valdecantos, MD³; Tianshuang Wu, PhD³; Kristian Reich, MD⁴¹Charles Institute of Dermatology, University College, Dublin, Ireland; ²Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, California, USA; ³AbbVie Inc, North Chicago, Illinois, USA; ⁴Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany

Figure 1. IMMvent Study Design



Efficacy of Switching to Risankizumab Compared With Continued Adalimumab Treatment in Patients With Moderate-to-Severe Plaque Psoriasis

8110

Caitriona Ryan, MD¹; Jeffrey Crowley, MD²; Wendell C Valdecantos, MD³; Tianshuang Wu, PhD³; Kristian Reich, MD⁴¹Charles Institute of Dermatology, University College, Dublin, Ireland; ²Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, California, USA; ³AbbVie Inc, North Chicago, Illinois, USA; ⁴Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany

Figure 3. PASI 90 Responses Through Week 44 in Part B Among PASI 50 to <90 Responders (NRI)

